IHC and DSP profiling of immune biomarkers in refractory cancer
Research type
Research Study
Full title
Immunohistochemistry and digital spatial profiling analysis of the tumour microenvironment of cancers which have the potential to express mutant p53, resulting in poor clinical response to current standard of care treatments.
IRAS ID
310177
Contact name
Gayle Marshall
Contact email
Sponsor organisation
pHion Therapeutics
Duration of Study in the UK
1 years, 1 months, 28 days
Research summary
Immunotherapy is one of most promising new treatment options for a range of different cancers including ovarian, breast and prostate. However, current immune targeted therapies have demonstrated minimal success. This is likely due to the microenvironment within the tumour, with expression of certain proteins or upregulation of certain cell types working against the treatment.
Immunotherapy has the potential to turn immune “cold” tumours “hot”, for example cancer vaccines encoding antigens designed to activate the cellular immune system to eradicate the tumour. For a cancer vaccine to be a success, tumours largely have to be immune “cold”. As such, for treatment success screening a patients tumour microenvironment is essential. This project is designed to profile TME and identify a range of markers that could be used to predict the efficacy of immunotherapy.
Analysis will be performed on a range of pre- and post-treatment biopsy cores stored within commercially available biobanks. Healthy control tissue will also be purchased from commercially available biobanks. Work will involve immunohistochemistry and proteomic analysis.
REC name
North West - Greater Manchester East Research Ethics Committee
REC reference
22/NW/0072
Date of REC Opinion
23 Feb 2022
REC opinion
Favourable Opinion